Agilent Technologies Inc (NYSE:A) stock fell 8.08% (As on May 24, 11:40:47 AM UTC-4, Source: Google Finance) after the company posted better than expected results for the second quarter of FY 23 driven by an innovative and broad portfolio, a differentiated customer experience, and outstanding execution. Agilent’s Life Sciences and Applied Markets Group (LSAG) reported second-quarter revenue of $968 million, a year-over-year increase of 8% (up 10% on a core basis). LSAG’s operating margin for the quarter was 27.3%. The Agilent CrossLab Group (ACG) reported second-quarter revenue of $387 million, a year-over-year increase of 10% (up 13% on a core basis). ACG’s operating margin for the quarter was 26.6%. The Diagnostics and Genomics Group (DGG) reported second-quarter revenue of $362 million, a year-over-year increase of 1% (up 3% on a core basis). DGG’s operating margin for the quarter was 20.2%. Non-GAAP net income of $377 million, up 12% from the second quarter of 2022.

Moreover, Pharma was led by biopharma which grew 16 percent driven by lab services, consumables, and our NASD business, while small molecule declined 1 percent. The chemicals and advanced materials business delivered strong results once again, growing 16 percent. The advanced materials segment grew more than 20 percent and the chemicals and energy segment grew double digits. During the quarter, the company had added additional strength to our LCMS product line by acquiring eMSion, and their innovative electron capture technology.

A in the second quarter of FY 23 has reported the adjusted earnings per share of $1.27, beating the analysts’ estimates for the adjusted earnings per share of $1.26. The company had reported the adjusted revenue growth of 6.8 percent to $1.72 billion in the second quarter of FY 23, beating the analysts’ estimates for revenue of $1.67 billion. Operating margins for the quarter are 25.6 percent, up 30 basis points.

Agilent Technologies expects Q3 2023 EPS to be in the range of $1.36-$1.38 versus the analyst consensus of $1.43. Agilent Technologies expects Q3 2023 revenue to be in the range of $1.64B-$1.68B versus the analyst consensus of $1.77B.

Agilent Technologies expects FY 2023 EPS to be in the range of $5.60-$5.65 versus the analyst consensus of $5.69. Agilent Technologies expects FY 2023 revenue to be in the range of $6.93B-$7.03B, representing reported growth of 1.2% to 2.7% versus the analyst consensus of $7.09B.